CJ-13,610 (hydrochloride)

CJ-13,610 (hydrochloride) is an orally active and potent nonredox-type 5-lipoxygenase inhibitor with an IC50 value of 0.07 μM. CJ-13,610 (hydrochloride) competes with activating LOOH at a regulatory LOOH-binding site with high affinity, thereby preventing 5-lipoxygenase catalysis. CJ-13,610 (hydrochloride) is promising for research of diseases related to elevated levels of 5-lipoxygenase such as inflammatory reactions, allergic asthma, various types of cancer and atherosclerosis[1].

Product Specifications

CAS Number

[179420-27-0]

UNSPSC

12352005

Target

Lipoxygenase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Cancer; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/cj-13-610-hydrochloride.html

Smiles

NC(C1(C2=CC(SC3=CC=C(N4C(C)=NC=C4)C=C3)=CC=C2)CCOCC1)=O.Cl

Molecular Formula

C22H24ClN3O2S

Molecular Weight

429.96

References & Citations

[1]Fischer L, et al. Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610. Br J Pharmacol. 2004 Jul;142 (5) :861-8.